Methodological and Mechanistic Advances in Evaluating the Antidiabetic Activity of Plant Extracts

Plant extracts remain central to antidiabetic discovery because their phytochemicals influence biochemical, cellular and physiological pathways linked with glucose regulation. These preparations inhibit digestive enzymes, modulate insulin-linked signalling, reduce oxidative stress, suppress inflammatory mediators and support β-cell resilience. Reported activity depends on methodological design and assay calibration. Recent advances strengthened early evaluation through refined in vitro enzyme assays, glucose handling models and calibrated cellular platforms. In vivo studies provide clearer evidence of glycaemic modulation, lipid correction and tissue protection when dosing and induction conditions are reported with full transparency. In silico systems reinforce laboratory findings through predicted multi-target binding profiles and ligand-stability modelling. Multi-omics technologies deepen mechanistic interpretation by mapping metabolite shifts, transcriptional responses and proteomic patterns that connect extract chemistry with metabolic outcomes. Integrated workflows now combine chemical profiling with in vitro, in vivo and computational systems to enhance reproducibility and improve mechanistic resolution across methodological tiers. Persistent challenges include extraction heterogeneity, assay variability, incomplete standardisation and uncertainty regarding model translatability across experimental tiers. This review examines methodological and mechanistic advances that strengthen the reliability and interpretability of plant-derived antidiabetic research.